Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M207,707Revenue $M49,605Net Margin (%)18.4Z-Score2.7
Enterprise Value $M208,617EPS $1.4Operating Margin %25.6F-Score6
P/E(ttm))23.8Cash Flow Per Share $3.5Pre-tax Margin (%)24.7Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %2.6Quick Ratio2.4Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %4.4Current Ratio2.7Lower Leverage y-yN
Price/Cash Flow7.2y-y EBITDA Growth Rate %-13.3ROA % (ttm)5.3Higher Current Ratio y-yY
Dividend Yield %3.1Insider Buy (3m)0ROE % (ttm)12.0Less Shares Outstanding y-yY
Payout Ratio %74.0Shares Outstanding M6,301ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactup Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEJohn Hussman 2014-03-31 Buy 0.04%$29.66 - $32.75
($31.36)
$ 33.978%New holding, 17000 sh.17,000
PFEJoel Greenblatt 2014-03-31 Add0.38%$29.66 - $32.75
($31.39)
$ 33.978%Add 356.54%1,014,808
PFEIrving Kahn 2014-03-31 Add0.98%$29.66 - $32.75
($31.36)
$ 33.978%Add 11.22%2,112,819
PFEJean-Marie Eveillard 2014-03-31 Reduce-0.19%$29.66 - $32.75
($31.39)
$ 33.978%Reduce -22.77%7,866,473
PFENWQ Managers 2014-03-31 Reduce-0.39%$29.66 - $32.75
($31.39)
$ 33.978%Reduce -13.6%9,231,207
PFEVanguard Health Care Fund 2014-03-31 Reduce-0.48%$29.66 - $32.75
($31.36)
$ 33.978%Reduce -40.13%7,276,622
PFERay Dalio 2013-12-31 Add0.01%$28.24 - $32.2
($30.7)
$ 33.9711%Add 102.18%110,408
PFERonald Muhlenkamp 2013-12-31 Add0.05%$28.24 - $32.2
($30.7)
$ 33.9711%Add 29.15%45,129
PFEJoel Greenblatt 2013-12-31 Add0.11%$28.24 - $32.2
($30.7)
$ 33.9711%Add 241.71%222,280
PFEJean-Marie Eveillard 2013-12-31 Add0.16%$28.24 - $32.2
($30.7)
$ 33.9711%Add 23.07%10,186,005
PFERobert Bruce 2013-12-31 Add0.17%$28.24 - $32.2
($30.7)
$ 33.9711%Add 4.63%452,000
PFEDonald Yacktman 2013-12-31 Sold Out -0.01%$28.24 - $32.2
($30.7)
$ 33.9711%Sold Out0
PFENWQ Managers 2013-12-31 Reduce-0.12%$28.24 - $32.2
($30.7)
$ 33.9711%Reduce -3.88%10,684,522
PFEDavid Dreman 2013-12-31 Reduce-0.15%$28.24 - $32.2
($30.7)
$ 33.9711%Reduce -85.73%10,163
PFECharles Brandes 2013-12-31 Reduce-0.22%$28.24 - $32.2
($30.7)
$ 33.9711%Reduce -9.32%5,767,402
PFEVanguard Health Care Fund 2013-12-31 Reduce-0.91%$28.24 - $32.2
($30.7)
$ 33.9711%Reduce -43.19%12,153,122
PFEIrving Kahn 2013-12-31 Reduce-2.55%$28.24 - $32.2
($30.7)
$ 33.9711%Reduce -24.25%1,899,759
PFERay Dalio 2013-09-30 Buy 0.01%$27.65 - $29.67
($28.69)
$ 33.9718%New holding, 54608 sh.54,608
PFEJoel Greenblatt 2013-09-30 Add0.04%$27.65 - $29.67
($28.69)
$ 33.9718%Add 259.55%65,050
PFEJean-Marie Eveillard 2013-09-30 Add0.44%$27.65 - $29.67
($28.69)
$ 33.9718%Add 174.32%8,276,410
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PFE Richard Pzena 2014-12-312,170,5680.030.36New Buy
PFE Jean-Marie Eveillard 2014-12-315,272,9430.080.4+3786.85%
PFE Vanguard Health Care Fund 2014-12-3119,395,6220.311.4+29.88%
PFE John Keeley 2014-12-3199,95900.06+2.69%
PFE James Barrow 2014-12-3162,760,16312.6+0.95%
PFE Robert Bruce 2014-12-31455,3320.013.9+0.74%
PFE Charles Brandes 2014-12-316,272,0970.12.8+0.24%
PFE NWQ Managers 2014-12-316,349,3770.12.4+0.17%
PFE Brian Rogers 2014-12-3112,737,1150.21.4
PFE Prem Watsa 2014-12-31235,00000.47
PFE Ruane Cunniff 2014-12-3110,96700
PFE Dodge & Cox 2014-12-3147,195,5730.751.4-0.86%
PFE Ken Fisher 2014-12-3131,196,4150.52-1.6%
PFE David Dreman 2014-12-3114,79200.04-1.65%
PFE Ronald Muhlenkamp 2014-12-3138,40900.24-2.76%
PFE Irving Kahn 2014-12-311,883,2170.0310.1-5.14%
PFE Mario Gabelli 2014-12-31951,5830.020.15-7.03%
PFE Joel Greenblatt 2014-12-311,420,9480.020.36-12.4%
PFE Ray Dalio 2014-12-31211,20800.05-28.43%
PFE Michael Price 2014-12-31000Sold Out
PFE Mark Hillman 2013-12-3123,98201.1
Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-02-13Sell104,000$34.73-0.49view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-12Sell9,000$34.85-0.83view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell14,800$34.30.76view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell80,200$34.230.96view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-10Sell9,000$33.782.31view
MADDALUNA ANTHONY JExecutive Vice President 2014-12-08Sell6,500$328view
HILL CHARLES HExecutive Vice President 2014-11-10Sell8,285$30.1814.51view
YOUNG JOHN DGroup President 2014-11-07Sell21,600$29.8915.62view
DAMELIO FRANK AExecutive Vice President 2014-11-07Sell0$29.7816.05view
READ IAN CChairman & CEO 2014-10-30Sell67,500$29.7616.13view

Press Releases about PFE :

    Quarterly/Annual Reports about PFE:

      News about PFE:

      Articles On GuruFocus.com
      Novartis Goes A Step Forward In Treating Lung Cancer Mar 02 2015 
      Lower GDP Estimate Weighs on U.S. Indexes Feb 28 2015 
      Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
      Abner Herrman's Top Three Holdings Feb 26 2015 
      Preparing for an Interest Rate Increase Feb 25 2015 
      Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
      Pfizer Takes A Giant Leap In Treatment of Cancer Feb 12 2015 
      Analyzing Ken Fisher's Holdings: Pfizer Inc. (PFE) Feb 12 2015 
      The Dogs of the Dow Get Off to a Sluggish Start in 2015 Feb 11 2015 
      Best Stock Pick For Long Term Investors Feb 10 2015 


      More From Other Websites
      Following the big bucks to the exit Mar 03 2015
      Prevnar, Pfizer's pneumonia vaccine, okayed for adults in EU Mar 03 2015
      CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal... Mar 03 2015
      Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type... Mar 03 2015
      Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type... Mar 03 2015
      If You 'Want To Make A Good Drug Great' Cost Must Be Factored In Mar 03 2015
      Why we're cautious about 2015: Germany's Merck Mar 03 2015
      How A Strong Greenback Dollar Affects the Economy Mar 02 2015
      Elliott Management starts new position in Cubist Pharmaceuticals Mar 02 2015
      Mallinckrodt PLC (MNK), Pfizer Inc. (PFE): Healthcor Management’s Top 5 Health Stocks Mar 02 2015
      How To Trade The Biggest Gainers Among The Dow 30 Mar 02 2015
      The Zacks Analyst Blog Highlights: Boeing, Home Depot, Chevron, Pfizer and 3M - Press Releases Mar 02 2015
      Interested In Pharmaceutical Stocks? Try Novartis (ADR) Feb 27 2015
      Dow 30 Stock Roundup: Home Depot Beats, Chevron Issues $6B in Bonds - Analyst Blog Feb 27 2015
      Increased Mergers and Acquistions Help, But Headwinds Persist Feb 27 2015
      Kahn Brothers’ Top Picks to Close 2014, as Founder Irving Kahn Passes at 109 Feb 27 2015
      Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Feb 27 2015
      Stock Goes Nuts As Akorn Cracks Q4 EPS, '15 Views Feb 26 2015
      Pfizer, Novartis say meningitis vaccine scope too narrow Feb 26 2015
      Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Feb 26 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      SEENSCO
      ReplySEENSCO - 8 months ago
      PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK